Active	Status	Sponsor type	Region	Phase	Filter
4 Active 7 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Scheltens, Philip
NCT04191486 / 2018-003567-66: Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD	Completed	2	221	Europe, RoW	T-817MA, Placebo	FUJIFILM Toyama Chemical Co., Ltd.	Mild Cognitive Impairment	02/23	03/23
VIVIAD, NCT04498650 / 2019-003532-23: A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD	Completed	2	259	Europe	PQ912, varoglutamstat, Placebo	Vivoryon Therapeutics N.V., Nordic Bioscience A/S, Amsterdam UMC, location VUmc	Early Alzheimers Disease, Mild Cognitive Impairment Due to AD	12/23	01/24
NCT04445831: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease	Completed	1/2	57	Europe	ACI-35.030, Placebo, JACI-35.054	AC Immune SA, Janssen Research & Development, LLC	Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment, Dementia, Brain Diseases, Central Nervous System Diseases	09/23	09/23
Prins, Niels D
SHINE, NCT03507790 / 2022-002326-27: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.	Completed	2	153	Europe, US, RoW	CT1812, Study Drug, Placebo, Matching Placebo	Cognition Therapeutics, National Institute on Aging (NIA)	Mild to Moderate Alzheimer's Disease	05/24	05/24
Meulen, Lea ter
No trials found
Boer, Casper de
No trials found